Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging

NCT ID: NCT00693758

Last Updated: 2011-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ability of a new SSFP-based BOLD MRI sequence to assess myocardial oxygenation changes in response to coronary flow changes induced by adenosine and increased CO2-partial pressure will be examined in healthy volunteers and patients with suspected coronary artery disease. Also the susceptibility of a new SSFP-based BOLD sensitive MRI sequence to changes in arterial oxygenation will be examined. This will help understand the physiologic basis of oxygen sensitive imaging of the heart.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A new SSFP based T2 and T2\* sensitive sequence which provides good BOLD contrast will be used. It was developed by researchers at the Stephenson CMR Centre and Northwestern University of Chicago. Its major advantage to previous BOLD sensitive sequences is its lower susceptibility to motion artifacts.

MR imaging is performed with a commercial 1.5 T Siemens MR scanner (Siemens Avanto). In order to obtain a homogeneous magnetic field an additional surface chest coil is used in combination to the body coil. Three short axis views representing basal, mid and apical slices are set up and are used throughout the study. If the volunteer has to be moved from their position for any reason, similar short axis views will be attempted.

In order to improve and further develop the MRI sequence the technique will be used in a arm-cuff model in healthy volunteers, using reactive hyperemia, which is easier to image than the heart. The BOLD-MRI signal intensity of the forearm will be assessed during a short, 3 min. lasting upper arm-cuff occlusion and the following reactive hyperemia.

Main interest of the study is the examination of the heart of healthy volunteers as well as patients with suspected coronary heart disease with this BOLD-MRI technique. The signal intensity of the myocardium at rest and after different coronary flow stimulation will be assessed. These stimuli will be pharmacologic (adenosine) as well as changes in arterial CO2 and O2 pressure.

All subjects that will undergo changes in their breathing gases, will first be examined in the vascular research laboratory of Dr. M. Poulin. There the subjects will be familiarized with the modified end-tidal forcing system (MEFS) and their individual response to changes in breathing gases will be assessed. A complete dry-run of the breathing protocol will be performed including 2 capillary blood gas analysis. On a second day subjects will be studied in the temperature-controlled MR scanning room at Stephenson CMR Centre in a fasting state for the previous 4 hours. This includes refrain from caffeine and nicotine in these preceding 4 hours. Prior to baseline scanning, capillary blood will be sampled from the finger for blood gas, hemoglobin and hematocrit analysis. Thereafter, the volunteer will be connected to the MEFS. A baseline scan will then be performed comprising of localization, cine imaging, cross sectional flow measurement of the coronary sinus (CS) and BOLD MRI of three representative short axis slices. Then an intravenous adenosine infusion will be started. After 3 min. MR scan will be repeated. After 5 min. of rest another baseline will be recorded. Then successively the carbon dioxide pressure will be increased in two steps to 40 and 45 mmHg. After a resting period of 5 min, another baseline scan will be performed. Then oxygen partial pressure of the inspired air will be reduced in 3 steps as described in the following paragraph until an inspiratory oxygen partial pressure of 45 mmHg is achieved. This will reflect an arterial oxygen saturation of approximately 90, 85 and 80%. At each step, BOLD MRI (3 axial slices) and cross sectional flow measurements of CS will be performed. Following 5 minutes of rest another baseline scan will be performed. Throughout experimentation the subject will be connected to the METFS and we will measure ventilation, blood pressure (noninvasive), heart rate (electrocardiogram) and arterial oxygen saturation (pulse oximetry).

Image-analysis: A region of interest will be drawn around the myocardium of each short axis. The averaged signal intensity is assessed and compared to baseline after adenosine infusion and at the different levels of arterial oxygenation and carbon dioxide concentration. Additionally, differential analysis for subendocardium and subepicardium will be performed.

Coronary flow in the coronary sinus will be calculated using phase contrast MRI. This technique was first described by van Rossum, validated in phantoms and animal studies and successfully used in human patient studies. Because of the relatively small diameter of the CS, absolute flow values may not be very accurate; therefore the relative change between different levels of hypoxia will be calculated.

End-points:

BOLD SI in the myocardium defined as the averaged signal intensity of the myocardium.

Relative flow changes in CS to baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Diseases Myocardial Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

healthy volunteers without intervention

Group Type NO_INTERVENTION

Breathing gas

Intervention Type DEVICE

Changes in pO2 and pCO2 in inspired air mix

2

patients with suspected coronary artery disease without intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

3

Healthy volunteers during adenosine infusion

Group Type EXPERIMENTAL

adenosine

Intervention Type DRUG

intravenous infusion of adenosine (140microgr./min/kg)

Blood pressure cuff

Intervention Type DEVICE

supra-systolic arm occlusion with pressure cuff

4

Healthy volunteers during changes of breathing gases (CO2, O2)

Group Type EXPERIMENTAL

modified end-tidal forcing system

Intervention Type OTHER

changes in partial pressures of O2 and CO2 in inspired air

5

patients with suspected coronary artery disease during adenosine infusion

Group Type EXPERIMENTAL

adenosine

Intervention Type DRUG

intravenous infusion of adenosine (140microgr./min/kg)

6

patients with suspected coronary artery disease during changes of breathing gases

Group Type EXPERIMENTAL

modified end-tidal forcing system

Intervention Type OTHER

changes in partial pressures of O2 and CO2 in inspired air

7

Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences

Group Type EXPERIMENTAL

arm cuff occlusion

Intervention Type OTHER

3 min. lasting upper arm cuff occlusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adenosine

intravenous infusion of adenosine (140microgr./min/kg)

Intervention Type DRUG

modified end-tidal forcing system

changes in partial pressures of O2 and CO2 in inspired air

Intervention Type OTHER

arm cuff occlusion

3 min. lasting upper arm cuff occlusion

Intervention Type OTHER

Breathing gas

Changes in pO2 and pCO2 in inspired air mix

Intervention Type DEVICE

Blood pressure cuff

supra-systolic arm occlusion with pressure cuff

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adenosine stress O2 / CO2 changes in inspired air

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed written consent
* age \> 18 years
* no known cardiovascular disease and no vasoactive medication (if recruited as healthy volunteer)
* suspected coronary artery disease or microvascular dysfunction (if recruited as patient)
* no known obstructive or restrictive lung disease
* fasting for 4 hours prior to the study

Exclusion Criteria

* Contraindications for MRI
* Known obstructive or restrictive lung disease
* concomitant serious medical condition
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Calgary

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Oliver Strohm

Adunct Research Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matthias Friedrich, MD

Role: PRINCIPAL_INVESTIGATOR

University of Calgary

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stephenson CMR Centre at Foothills Medical Centre, University of Calgary

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18798

Identifier Type: -

Identifier Source: secondary_id

18798

Identifier Type: -

Identifier Source: org_study_id